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Abstract
CCG-1423 suppresses several pathological processes including cancer cell migration, tis-
sue fibrosis, and the development of atherosclerotic lesions. These suppressions are
caused by inhibition of myocardin-related transcription factor A (MRTF-A), which is a critical
factor for epithelial–mesenchymal transition (EMT). CCG-1423 can therefore be a potent
inhibitor for EMT. CCG-1423 and related compounds, CCG-100602 and CCG-203971 pos-
sess similar biological activities. Although these compounds are comprised of two stereo-
isomers, the differences in their biological activities remain to be assessed. To address this
issue, we stereoselectively synthesized optically pure isomers of these compounds and val-
idated their biological activities. The S-isomer of CCG-1423 rather than the R-isomer exhib-
ited modestly but significantly higher inhibitory effects on the cellular events triggered by
MRTF-A activation including serum response factor-mediated gene expression and cell
migration of fibroblasts and B16F10 melanoma cells. Accordingly, the S-isomer of CCG-
1423 more potently blocked the serum-induced nuclear import of MRTF-A than the R-iso-
mer. No such difference was observed in cells treated with each of two stereoisomers of
CCG-100602 or CCG-203971. We previously reported that the N-terminal basic domain
(NB), which functions as a nuclear localization signal of MRTF-A, is a binding site for CCG-
1423. Consistent with the biological activities of two stereoisomers of CCG-1423, docking
simulation demonstrated that the S-isomer of CCG-1423 was more likely to bind to NB than
the R-isomer. This is a first report demonstrating the stereospecific biological activities of
CCG-1423.
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Introduction
Epithelial–mesenchymal transition (EMT) is closely linked with cancer cell migration and tis-
sue fibrosis. The activation of myocardin-related transcription factor A (MRTF-A/MAL/
MKL1), a transcriptional cofactor for serum response factor (SRF), plays a pivotal role in these
pathological processes [1–3]. MRTF-A is also involved in other biological events including
development of mammary myoepithelial cells [4, 5], skeletal muscle differentiation [6], and
neointimal formation in atherosclerotic lesions [7].
MRTF-A is primarily located in the cytoplasm, but transiently translocates to the nucleus in
response to Rho activation. We have recently shown that importin α/β1 heterodimer regulates
the nuclear import of MRTF-A in response to Rho activation-induced depletion of G-actin [8].
The N-terminal basic domain (NB) of MRTF-A (B2 [9] or NLS2 [10]), which is positioned
between the second and third RPEL motifs, functions as a binding site for importin α/β1 het-
erodimer. Treisman and co-workers proposed that the importin α/β1 heterodimer interacts
with a bipartite nuclear localization signal (NLS) including NB and another N-terminal basic
domain (B3) in the second RPEL motif [9], which is also known as NLS1 [10].
CCG-1423, an inhibitor of Rho signaling [11], blocks the nuclear import of MRTF-A. Treat-
ment with CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose
uptake and tolerance in insulin-resistance mice in vivo [12]. This finding suggests that
MRTF-A/SRF-mediated pathway is an important target for the development of novel thera-
peutics for insulin resistance and type 2 diabetes. Furthermore, CCG-1423 inhibits the develop-
ment of atherosclerotic lesions by reduction in neointimal formation [7]. Thus, these findings
suggest that MRTF-A can be an attractive molecular target for drug discovery.
Recently, we have revealed the inhibitory mechanism of CCG-1423 in the nuclear accumu-
lation of MRTF-A. CCG-1423 binds to NB of MRTF-A and inhibits the nuclear import of
MRTF-A by masking the NLS [13]. Furthermore, CCG-1423 is suggested to bind other mole-
cules such as MICAL-2, an atypical actin-regulatory protein [14] and Phactr1, a RPEL contain-
ing protein [13], indicating the possibility of other mode of CCG-1423. Recent studies reported
that CCG-1423 related compounds CCG-100602 and CCG-203971 prevent the nuclear accu-
mulation of MRTF-A in colon and lung fibroblasts [15, 16]. Although each of these com-
pounds is comprised of two stereoisomers, arising from an asymmetric center indicated in Fig
1, the differences in their biological activities remain unclear. It is clinically and pharmaceuti-
cally significant to reveal their active structures because the commercially available compounds
are a mixture of two stereoisomers. In this study, we stereoselectively synthesized optically
pure isomers of CCG-1423 and related compounds (Fig 1), which were developed by Neubig
and co-workers. They focused on the inhibitory potential in Rho/ MRTF-A/SRF-mediated
pathway [11, 17–19]. We then validated their biological activities and analyzed their binding to
MRTF-A by molecular docking simulations. This is a first report demonstrating the stereospe-
cific biological activities of chemical compounds inhibiting the MRTF-A function.
Materials and Methods
Chemistry
Optical rotations were measured on a PerkinElmer 341 automatic polarimeter (PerkinElmer,
Inc., Waltham, MA, USA). NMR spectra were obtained on JEOL JNM-ECA600 (600 MHz for
1H) or JEOL JNM-AL300 (300 MHz for 1H) spectrometers (JEOL Ltd, Tokyo, Japan). Chemi-
cal shifts are reported in parts per million relative to the internal standards [tetramethylsilane
(0.00 ppm) for 1H; CD3OD (49.00 ppm) for
13C]. High performance liquid chromatography
(HPLC) was carried out using a Shimadzu LC-10AT VP HPLC system and SPD-10A VP UV
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detector (Shimadzu Corp., Kyoto, Japan) with CHIRALPAK AD or OD (4.6F × 250 mm; Dai-
cel Corporation, Osaka, Japan; detection: UV 254 nm, eluent: n-hexane/ethanol, flow rate: 1.0
ml/min, temperature: 30°C).
Thin layer chromatography was carried out using silica gel plates (Merck 5715, 0.25 mm;
Merck KGaA, Darmstadt, Germany). Silica gel flash column chromatography was carried out
using a Biotage Isolera One chromatograph (Biotage AB, Uppsala, Sweden) with Biotage
SNAP Ultra cartridges (silica gel, 25 μm). Methyl (R)-lactate and benzyl (S)-lactate were pur-
chased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Both the stereoisomers of 1-
(tert-butoxycarbonyl)piperidine-3-carboxylic acid were purchased from Alfa Aesar, A Johnson
Matthey Company (Heysham, Lancashire, UK). The outline of synthesis of the S-isomer of
CCG-1423 is summarized in Fig 2.
Benzyl (R)-lactate (2) [20]. A mixture of methyl (R)-lactate (1) (5.21 g, 50.0 mmol), ben-
zyl alcolol (5.42 g, 50. 1 mmol), iron(III) acetylacetonate (880 mg, 2.49 mmol), sodium carbon-
ate (270 mg, 2.55 mmol) and heptane (500 ml) was refluxed for 12 h with Dean-Stark
apparatus. To the cooled reaction mixture was added silica gen (60 ml) and the solvent was
removed under reduced pressure. The residue was subjected to silica gel flash column chroma-
tography (hexane/ethyl acetate = 80/20 ~ 50/50) to afford the title compound (7.83 g, 87%) as a
yellow oil. 1H NMR (300 MHz, CDCl3) δH: 1.43 (3H, d, J = 6.8 Hz), 2.80 (1H, d, J = 5.3 Hz),
4.32 (1H, qd, J = 6.8 and 5.3 Hz), 5.21 (2H, s), 7.29–7.41 (5H, m).
Benzyl (S)-2-[(phthalimido)oxy]propanoate (3) [21]. To an ice-cooled mixture of com-
pound 2 (3.30 g, 18.3 mmol), N-hydroxyphthalimide (3.00 g, 18.4 mmol), triphenylphosphine
(4.80 g, 18.3 mmol) in anhydrous tetrahydrofuran (40 ml) was added dimethyl azodicarboxy-
late (2.0 ml, 18.2 mmol) dropwise and the mixture was stirred for 1 h at room temperature
(RT). The reaction mixture was diluted with ethyl acetate followed by addition of silica gel (80
ml). The solvent was removed reduced pressure and the residue was subjected to silica gel flash
column chromatography (hexane/ethyl acetate = 85/15 ~ 50/50) to afford the title compound
(3.78 g, 63%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δH: 1.65 (3H, d, J = 6.9 Hz), 4.92
(1H, q, J = 6.9 Hz), 5.17 (1H, d, J = 12.3 Hz), 5.24 (1H, d, J = 12.3 Hz), 7.28–7.37 (5H, m), 7.71–
7.77 (2H, m), 7.79–7.85 (2H, m).
(S)-2-[(Phthalimido)oxy]propanoic acid (4) [21]. Amixture of compound 3 (3.77 g, 11.6
mmol) and 5% palladium on activated carbon (410 mg) in methanol (40 ml) was stirred for 2 h
under hydrogen atmosphere (1 atm). The catalyst was removed through a pad of Cellite and
the filtrate was concentrated under reduced pressure to afford the title compound (2.55 g, 94%)
as a pale yellow solid. This was used without purification. 1H NMR (300 MHz, CDCl3) δH: 1.73
(3H, d, J = 6.9 Hz), 4.89 (1H, q, J = 6.9 Hz), 7.56 (1H, br s), 7.75–7.89 (4H, m).
(S)-N-(4-Chlorophenyl)-2-[(phthalimido)oxy]propanamide (5). To an ice-cooled mix-
ture of compound 4 (265 mg, 1.13 mmol) and catalytic amount of N,N-dimethylformamide in
anhydrous dichloromethane (2.5 ml) was added oxalyl chloride (0.20 ml, 2.35 mmol) and the
mixture was stirred for 1 h at RT. The reaction mixture was concentrated under reduced
Fig 1. Chemical structures of racemic CCG-1423, CCG-100602, and CCG-203971. The asterisks (*) represent asymmetric centers.
doi:10.1371/journal.pone.0136242.g001
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pressure to give (S)-2-[(phthalimido)oxy]propanoyl chloride as a yellow oil. 1H NMR (300
MHz, CDCl3) δH: 1.80 (3H, d, J = 6.9 Hz), 5.17 (1H, q, J = 6.9 Hz), 7.75–7.82 (2H, m), 7.84–
7.90 (2H, m). This material was dissolved in anhydrous dichloromethane (2.5 ml) and cooled
with the ice-bath. To the solution was added 4-chloroaniline (300 mg, 2.35 mmol) dissolved in
anhydrous dichloromethane (5.0 ml) dropwise, and the mixture was stirred for 2 h at 0°C. The
reaction mixture was diluted with ethyl acetate (50 ml) and washed successively with 2N HCl,
water, and brine (20 ml each). The organic layer was dried over anhydrous magnesium sulfate
and concentrated under reduced pressure. The residue was purified by silica gel flash column
chromatography (hexane/ethyl acetate = 75/25 ~ 50/50) to afford the title compound (255 mg,
66%) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δH: 1.78 (3H, d, J = 7.0 Hz), 4.84 (1H,
q, J = 7.0 Hz), 7.31 (2H, d, J = 9.0 Hz), 7.71 (2H, d, J = 9.0 Hz), 7.77–7.82 (2H, m), 7.84–7.90
(2H, m), 9.68 (1H, br s).
(S)-2-Aminooxy-N-(4-chlorophenyl)propanamide (6). To a suspension of compound 5
(215 mg, 0.624 mmol) in methanol (10 ml) was added hydrazine monohydrate (143 mg, 2.86
mmol) and the mixture was stirred for 5 min at RT. The reaction mixture was concentrated
under reduced pressure, diluted with water (25 ml), and acidified with 2N HCl (0.5 ml). The
insoluble materials were filtered off and the filtrate was washed with ethyl acetate (3 × 20 ml).
The aqueous layer was cooled to 0°C, and to the solution was added sodium hydroxide (913
mg) followed by extraction with diethyl ether (3 × 20 ml). The combined organic layer was
washed successively with water and brine (15 ml each), dried over anhydrous magnesium sul-
fate, and concentrated under reduced pressure to afford the title compound (69.8 mg, 52%) as
a pale yellow solid. This was used without purification. 1H NMR (300 MHz, CDCl3) δH: 1.45
(3H, d, J = 6.9 Hz), 4.23 (1H, q, J = 6.9 Hz), 5.66 (2H, br s), 7.29 (2H, d, J = 8.8 Hz), 7.53 (2H, d,
J = 8.8 Hz), 8.15 (1H, br s).
(S)-2-{[3,5-Bis(trifluoromethyl)benzoyl]aminooxy}-N-(4-chlorophenyl)propanamide
(CCG-1423 S). To a mixture of compound 6 (69.8 mg, 0.325 mmol), 3,5-bis(trifluoromethyl)
benzoic acid (91.8 mg, 0.356 mmol), 4-dimethylaminopyridie (62.4 mg, 0.511 mmol) in anhy-
drous dichloromethane (3.5 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (82.7 mg, 0.431 mmol) and the mixture was stirred for 1 h at RT. The reaction
mixture was diluted with ethyl acetate (50 ml), and washed successively with 2N HCl, water
saturated aqueous sodium hydrogen carbonate solution, and brine (15 ml each). The organic
Fig 2. Synthesis of optically active CCG-1423 S. Reagents and conditions: (a) benzyl alcohol, iron(III) acetylacetonate, Na2CO3, heptane, reflux (–H2O),
12 h, 87%; (b) N-hydroxyphthalimide, dimethyl azodicarboxylate, PPh3, THF, RT, 1 h, 63%; (c) H2, Pd-C, MeOH, RT, 2 h, 94%; (d) (COCl)2, N,N-
dimethylformamide, CH2Cl2, RT, 1 h; (e) 4-chloroaniline, CH2Cl2, 0°C, 2 h, 66% (2 steps); (f) NH2NH2-H2O, MeOH, RT, 5 min, 52%; (g) 3,5-bis
(trifluoromethyl)benzoic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 4-dimethylaminopyridine, CH2Cl2, RT, 1 h, 79%.
doi:10.1371/journal.pone.0136242.g002
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layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
The residue was purified by silica gel flash column chromatography (hexane/ethyl acetate = 70/
30 ~ 50/50) to afford the title compound (117 mg, 79%) as a colorless solid. 1H NMR (600
MHz, CD3OD) δH: 1.60 (3H, d, J = 6.8 Hz), 4.66 (1H, q, J = 6.8 Hz), 7.31 (2H, d, J = 8.6 Hz),
7.68 (2H, d, J = 8.6 Hz), 8.17 (1H, br s), 8.39 (2H, s). 13C NMR (151 MHz, CD3OD) δC: 17.48,
83.79, 122.59 (2C), 124.47 (2C, q, JC-F = 272 Hz), 126.34 (br), 128.89 (2C, q, JC-F = 4.3 Hz),
129.86 (2C), 130.45, 133.17 (2C, q, JC-F = 33.3 Hz), 135.49 (br), 138.02, 172.16, 172.19. The spe-
cific rotation ([α]D), retention time (rt) and enantiomeric excess (ee) obtained in HPLC analy-
sis, are summarized in Table 1.
Antibodies and plasmids
Antibodies used in this study were as follows: anti-DYKDDDDK (anti-Flag) antibody (Trans
Genic, Kobe, Japan), anti-SMα−actin, anti-α−tubulin antibodies, and anti-Flag M2 affinity gel
(Sigma, St. Louis, MO), anti-myoD and anti-myogenin antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA), anti-myosin heavy chain (MHC) antibody (MF20) (Developmental Studies
Hybridoma Bank), and Alexa 568-conjugated secondary antibody (Molecular Probes, Eugene,
OR). Concerning a polyclonal anti-MRTF-A antibody, we described in detail previously [13].
Detail information about the plasmids used in this study was described elsewhere [8, 22].
Cell culture, promoter assay, and immunocytochemistry
Human normal skin fibroblast cell line CCD1059Sk was obtained from the American Type
Culture Collection (ATCC). NIH3T3 cells, human skin fibroblasts (ATCC, CRL-2072), and
B16F10 melanoma cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal calf serum. Transfection was performed using Trans IT-LT1 (Pan-
Vera Corporation, Madison, WI). After transfection, cells were cultured under serum-
stimulated conditions for 24 h and were treated with the indicated compounds for further 24 h.
Cell lysates were subjected to luciferase and β−galactosidase assays (luciferase assay kit [Pro-
mega] and β−galactosidase assay kit [Clonthec]). Relative promoter activity was expressed in
luminescence units normalized to the β−galactosidase activity of pSVβ−gal in the cell extracts.
These assays were performed in triplicate and were repeated three times. B16F10 cells were
stained with anti-MRTF-A antibody and Hoechst 33258. Fluorescent images were analyzed as
described previously [23]. The subcellular localization of MRTF-A was divided into three
groups: nuclear localization (N); diffuse distribution in the nucleus and throughout the cyto-
plasm (defined as equivalent immunostaining intensities of the target molecules in the cyto-
plasm and nucleus) (NC); and cytoplasmic localization (C). In each experiment (n = at least
three independent experiments), 100–200 cells were analyzed.
C2C12 myoblast differentiation
C2C12 myoblasts were usually cultured in DMEM supplemented with 20% fetal calf serum
(growth medium [GM]). To induce myogenic differentiation, the culture medium was changed
to DMEM supplemented with 2% horse serum (differentiation medium [DM]) at the time
point when cells became confluent. Whole cell lysates were prepared at the indicated time
point and were subjected to immunoblot (IB) analysis with the indicated antibodies. α−tubulin
was used as a loading control. These assays were repeated three times and representative data
were shown.
Stereospecific Biological Activities of CCG-1423
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Wound healing assay
Confluent cells were scratch-wounded with a 20 μl pipette tip. Cell migration was monitored
using a low-light inverted Olympus microscope (CKX 41) coupled with a monitoring system,
CellPad-E (Tucsen, Fujian, China) every 2 h for 10 h after scratching. Serial 5 images were ana-
lyzed with the NIH ImageJ software to quantify the migration area. Percentages indicate the
relative migration areas normalized by the migration areas of control cells treated with vehicle,
which was set at 100% (means ± SEMs of the results from five serial places). These assays were
repeated two and three times.
Methylthiazole tetrazolium, thiazolyl blue (MTT) assay
Cytotoxicity evaluation of the indicated compounds was performed using The PromoKine Cell
Proliferation Assay Kit IV (MTT) (PromoCell, Heidelberg, Germany). Approximately 1 × 104
B16F10 cells were seeded in a 96 well plate and were cultured for 24 h. Cells were treated with
the indicated concentrations of each of CCG-1423 and related compounds. After 24 h of incu-
bation, 10 μl of MTT reagent was added to each well and was further incubated for 4 h. Forma-
zan crystals formed in each well were dissolved in DMSO and the plates were read immediately
in a microplate reader, SH-9000Lab (CORONA ELECTRIC, Ibaraki, Japan) at 570 nm and 630
nm. These assays were performed in quadruplet and were repeated three times.
Preparation of cell extracts
The cytoplasmic and nuclear fractions were prepared as described previously [24], and the
respective fractions were subjected to IB with the indicated antibodies.
MRTF-A binding assay using CCG-1423 Sepharose
Preparation of affinity Sepharose covalently coupled with each of the stereoisomers of CCG-
1423 was performed based on previously reported methods [13]. MRTF-A protein was synthe-
sized in vitro using the TNT SP6 High-Yield Expression System based on an optimized wheat
germ extract (Promega) and was purified using anti-Flag M2 affinity gel. Mixtures of MRTF-A
protein (300 ng), 0.005% bovine serum albumin, and the indicated CCG-1423 Sepharose or
control Sepharose (bed volume 25 μl) in the pull-down (PD) buffer [13] (total 400 μl)] were
incubated at 4°C for 2 h with rotation. After washing the respective Sepharose with the PD
buffer and phosphate-buffered saline, the pull-downed MRTF-A protein was detected by IB.
Table 1. Selected properties of synthetic compounds.
compound R-isomer S-isomer
[α]D (°)
a) rt (min)b) ee (%)b) [α]D (°)
a) rt (min)b) ee (%)b)
CCG-1423 +107 43.7c) >99.9 –103 31.2c) >99.9
CCG-100602 –78 8.8d) 98.8 +79 5.4d) 99.0
CCG-203971 –88 11.3e) 99.0 +89 16.7e) 99.1
a) Measured in methanol; c 1; temperature: 27°C (CCG-1423), 25°C (CCG-100602 and CCG-203971).
b) Determined by HPLC, column: 4.6Φ × 250 mm; eluent: n-hexane/ethanol; flow rate: 1 ml/min; temperature: 30°C; detection: UV254 nm.
c) CHIRALPAK AD, n-hexane/ethanol = 200/3.
d) CHIRALPAK AD, n-hexane/ethanol = 85/15.
e) CHIRALPAK OD, n-hexane/ethanol = 85/15.
doi:10.1371/journal.pone.0136242.t001
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Docking simulation
In order to evaluate the docking precisely, the calculation of the ΔG of the ligand-protein bind-
ing is necessary; the ΔG of binding can be calculated using a number of different methods
based on molecular dynamics (MD) [25]. However, MD calculations are time consuming.
Therefore, scoring functions, where the enthalpy of interaction between the protein and ligand
is roughly estimated, were used to speed up the calculations. In this study, the rigid protein and
torsionally flexible ligand were employed to calculate a docking score, in which shape and
chemical functional complementarity are used. This scoring function is a Gaussian scoring
function, which is fundamentally smooth. Gaussian scoring can mimic small fluctuations in
protein conformation, allowing modeling of local receptor flexibility. Gaussian-smoothed
potentials are applied to measure the complementarity of ligand poses to the active site. In the
Chemgauss4 function [26] used in this study, shape interactions, hydrogen bonding interac-
tions with the protein, hydrogen bonding interactions with implicit solvent, and metal-chelator
interactions are considered. Comparison of docking simulation between the stereoisomers of
each ligand was done using the average of docking scores for the ten highest scored poses for
each stereoisomer to reduce the influence of score fluctuation. Prior to running the docking,
conformers of each ligand molecule were generated using the conformer generating software,
OMEGA (OpenEye, Santa Fe, NM) [27, 28]. Since the conformers of each ligand are generated
independent of the active binding site, the running time required for docking experiment can
be reduced. In OMEGA, conformers with internal clashes or high strain are discarded, and low
strain conformers are clustered on the basis of root mean square deviation. The maximum
number of conformers generated by OMEGA is set as 200 in this study.
Crystal structure of the MRTF-A-importin α (PDB: 3TPM) was downloaded from NCBI
site (http://www.ncbi.nlm.nih.gov/) and the NLS2 (NB) or NLS1 binding site was excised from
the MRTF-A-importin α using MAKE_RECEPTOR tool of OEDocking (OpenEye, Santa Fe,
NM). To this excised binding pocket, two stereoisomers of CCG-1423 were docked using Fast
Exhaustive Docking of OEDocking (OpenEye, Santa Fe, NM) [26].
Statistical analysis
Results are given as means and standard errors. Statistical analysis was performed using a two-
tailed paired student t-test or a two-way ANOVA when there were multiple data points. The
significance level is set at 0.05.
Results
Chemistry
The synthesis of chiral CCG-1423 is outlined in Fig 2. Commercially available methyl (R)-lac-
tate (1) was transesterified by benzyl alcohol in the presence of an iron catalyst [20] to afford
benzyl (R)-lactate (2) in 87% yield. Subsequent Mitsunobu reaction using N-hydroxyphthali-
mide [21] afforded protected hydroxylamine derivative 3 with stereoconversion at the α-posi-
ton of the ester carbonyl group. The benzyl ester of compound 3 was removed under catalytic
hydrogenation condition to furnish free carboxylic acid 4. Benzyl ester was suitable in the syn-
thesis since phthalimide group was not stable under strong basic hydrolytic condition.
Next, carboxylic acid 4 was treated with oxalyl chloride in the presence of catalytic amount
of N,N-dimethylformamide, before the resulting acid chloride was reacted with 4-chloroaniline
to afford amide 5 in 66% yield. It is noteworthy that standard amidation protocol using carbo-
diimide coupling reagent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochlo-
ride (EDCl) and base affected N-hydroxyphthalimide moiety. In this case, N-(4-chlorophenyl)
Stereospecific Biological Activities of CCG-1423
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phthalimide was isolated as a major product (37–48% yield) and no desired product was
obtained. The phthalimide group of compound 5 was hydrolyzed by hydrazine monohydrate
to afford free hydroxylamine 6 in 52% yield. Finally, compound 6 was condensed with 3,5-bis
(trifluoromethyl)benzoic acid using EDCl as a coupling reagent and 4-dimethylaminopyridine
as a base to furnish desired chiral CCG-1423 (CCG-1423 S) in 79% yield. The R-isomer of
CCG-1423 (CCG-1423 R) was synthesized from commercially available benzyl (S)-lactate by
the same method outlined in Fig 2. The chiral isomers of CCG-100602 and CCG-203971 were
synthesized according to the literature method [17, 19] from (R) or (S)-1-(tert-butoxycarbo-
nyl)piperidine-3-carboxylic acid. The selected properties of synthetic chiral compounds were
summarized in Table 1. We confirmed optical purity of synthetic compounds by high perfor-
mance liquid chromatography (HPLC) using chiral columns. All pairs of stereoisomer could
be completely separated by CHIRALPAK AD or OD columns, and enantiomeric excess of syn-
thetic compounds was proved to be at least 98.8%.
Differences in biological activities between racemic and chiral CCG-
1423 stereoisomers
Firstly, we compared the effects of the racemic and chiral CCG-1423 on the transcription medi-
ated through MRTF-A/SRF by promoter assay in NIH3T3 fibroblasts. Treatment with racemic
(SR) or each of the stereoisomers of CCG-1423 [S-isomer (S) and R-isomer (R)] significantly
reduced SRF reporter activity (Fig 3A). We then examined the effects of the racemic and chiral
CCG-1423 on the migration of NIH3T3 fibroblasts. Treatment with the racemic and chiral
CCG-1423 suppressed their migration (Fig 3B). In both cases, the most potent reduction in
these activities was observed in cells treated with the S-isomer of CCG-1423. The hierarchy of
the inhibitory effects was S> SR> R. In accordance with these results, similar inhibition was
observed in the expression of endogenous SMα−actin protein in human skin fibroblasts (Fig
3C, upper panels). The expression of SMα−actin is also mediated through MRTF-A/SRF path-
way. Compared with the inhibitory effect on SRF-mediated transcription by CCG-1423
(1 μM), high doses of CCG-1423 (5 to 10 μM) were necessary for the reduction of SMα−actin
expression at the protein levels. Similar hierarchy (S> SR> R) was also observed in the cell
migration of human skin fibroblasts (Fig 3C, lower panel). MRTF-A is also involved in myo-
genesis [29]. Rho signaling-induced activation of MRTF-A in C2C12 myoblasts plays a critical
role in their myogenic differentiation [6]. Thus, we examined the effects of the racemic and chi-
ral CCG-1423 on C2C12 myoblast differentiation. Monitoring the expression of myogenic
markers suggested that treatment with the racemic and chiral CCG-1423 suppressed differenti-
ation of myoblast into myocyte (Fig 3D). In this case, the S-isomer also exhibited higher inhibi-
tion activity than the SR- and the R-isomers: the hierarchy was S> SR> R.
Differences in biological activities of the stereoisomers of CCG-1423 and
related compounds
CCG-1423 related compounds, namely CCG-100602 and CCG-203971 (Fig 1), are also com-
prised of two stereoisomers, but the differences in their biological activities have not yet been
characterized. We therefore addressed the effects of the stereoisomers of CCG-1423, CCG-
100602, and CCG-203971 on MRTF-A/SRF-mediated transcription by promoter assay (Fig 4).
Treatment with the respective stereoisomers of CCG-1423 and related compounds reduced
SRF reporter activity. However, among them, significant difference between the S- and the R-
isomers was only observed in cells treated with CCG-1423.
Activation of MRTF-A/SRF pathway plays a critical role in the migration but not in the pro-
liferation of B16 melanoma cells [30]. We therefore examined the effects of the stereoisomers of
Stereospecific Biological Activities of CCG-1423
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Fig 3. Effects of the racemic and chiral CCG-1423 on the cellular events mediated throughMRTF-A/SRF. (A) Promoter analysis using SRF-dependent
reporter gene. NIH3T3 cells were transfected with 500 ng of 3xCArG-Luciferase report plasmid, 200 ng of Flag-tagged MRTF-A expression plasmid, and 300
ng of pSVβ−gal. They were cultured for 48 h. For the last 24 h, they were treated with vehicle or 1 μM of racemic or chiral CCG-1423. The luciferase activity
with vehicle only (control [cntl] DMSO) was set at 100%. Each value represents the means ± SEMs of results from three independent experiments. Each
value represents the means ± SEMs of results from three independent experiments. Statistical differences were calculated using student’s t-test.
Stereospecific Biological Activities of CCG-1423
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CCG-1423 and related compounds on the migration of B16F10 cells (Fig 5A). Treatment with
these stereoisomers reduced cell migration in a dose-dependent manner. At any concentration
tested in this study, the S-isomer of CCG-1423 exhibited higher inhibitory potency than the R-
isomer of CCG-1423. However, no such difference was observed in cells treated with either
CCG-100602 or CCG-203971. We also analyzed the subcellular localization of endogenous
MRTF-A in B16F10 cells treated with each of these stereoisomers (Fig 5B and 5C, S2 Fig).
Serum-induced nuclear import of MRTF-A was modest in B16F10 cells; MRTF-A was diffusely
localized both in the nucleus and throughout the cytoplasm but was not localized only in the
nucleus in most of cells restimulated with serum. Treatment with these stereoisomers markedly
increased the proportion of cells exhibiting the cytoplasmic localization of MRTF-A, suggesting
that the nuclear import of MRTF-A is inhibited. The inhibitory effect of the S-isomer of CCG-
1423 was higher than that of the R-isomer. We also examined the cytotoxic effects of these
Significance levels were as follows: CCG-1423 SR vs CCG-1423 S, P = 0.00240; CCG-1423 SR vs CCG-1423 R, P = 0.01411; CCG-1423 S vs CCG-1423 R,
P = 0.00035. (B) Wound healing assay. Confluent cultures of NIH3T3 cells were pre-treated with 10 μM of each of the respective compounds or vehicle for 20
h, and then they were scratch-wounded with a 20 μl pipette tip. Bar = 25 μm (upper panel). Cell migration was monitored and quantified as described in
Materials and Methods (lower panel). Each value represents the means ± SEMs of results from three independent experiments. Statistical differences were
calculated using student’s t-test. Significance levels were as follows: CCG-1423 SR vs CCG-1423 S, P < 1 × 10−4; CCG-1423 SR vs CCG-1423 R,
P = 0.00143; CCG-1423 S vs CCG-1423 R, P < 1 × 10−8. High magnification images were shown in S1 Fig. (C) Effects on the expression of SM α−actin and
cell motility of fibroblasts. Human skin fibroblasts were cultured as described in Materials and Methods. For the last 48 h (upper IB analysis) or 20 h (lower cell
migration analysis), cells were treated with vehicle or the indicated concentrations of each of the racemic or chiral CCG-1423. Whole cell lysates were
subjected to IB analysis with anti-SM α−actin-antibody (upper panels). α−tubulin was used as a loading control. Dose-dependent effects of the respective
stereoisomers were analyzed using a two-way ANOVA. The dose-dependent effects between CCG-1423 S and CCG-1423 R were significantly different
(P < 1 × 10−4). Significance levels between bar graphs with a and between bar graphs with b were as follows: aP < 1 × 10−4 and bP < 1 × 10−4. Cell migration
was monitored and quantified as described above (lower panel). Each value represents the means ± SEMs of results from three independent experiments.
Statistical differences were calculated using student’s t-test. Significance levels were as follows: CCG-1423 SR vs CCG-1423 S, P = 0.05748; CCG-1423 SR
vs CCG-1423 R, P = 0.00834; CCG-1423 S vs CCG-1423 R, P = 0.00512. (D) Effect on the differentiation of skeletal myoblasts. C2C12 myoblasts were
initially cultured in GM for 2 days, and then were cultured in DM for 3 days. The experimental processes were schematically shown in the left column. White
and gray rectangles indicated the cultured period treated with vehicle or 10 μM of racemic or chiral CCG-1423, respectively. Whole cell lysates were prepared
at DM 3 day, and they were subjected to IB analysis (right column). α−tubulin was used as a loading control.
doi:10.1371/journal.pone.0136242.g003
Fig 4. Effects of the stereoisomers of CCG-1423 and related compounds on MRTF-A/SRF-mediated
transcriptional activity. Promoter assay in NIH3T3 cells. Detailed procedures were described in Materials
and Methods and the legend for Fig 3. For the last 24 h, cells were treated with vehicle or 0.3 μM of the
indicated compound. The luciferase activity with vehicle only (cntl DMSO) was set at 100%. Each value
represents the means ± SEMs of results from three independent experiments. Statistical differences were
calculated using student’s t-test. Significance levels were as follows: CCG-1423 S vs CCG-1423 R,
P = 0.01712; CCG-100602 S vs CCG-100602 R, P = 0.45219; CCG-203971 S vs CCG-203971 R,
P = 0.45621.
doi:10.1371/journal.pone.0136242.g004
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Fig 5. Effects of the stereoisomers of CCG-1423 and related compounds on cell migration and nuclear import of MRTF-A. (A) Confluent cultures of
B16F10 cells were pre-treated with the indicated concentrations of each of the respective compound or vehicle for 12 h, and then they were scratch-wounded
with a 20 μl pipette tip. Cell migration was monitored and quantified as described in Materials and Methods. Statistical differences were calculated using
student’s t-test. (B and C) B16F10 cells cultured in DMEM-10% serum were pre-treated with 3 μM of the indicated compound or vehicle for 12 h, and then
they were restimulated with serum for 15 min (final serum concentration 20%). Vehicle-treated B16F10 cells with or without serum restimulation were used as
Stereospecific Biological Activities of CCG-1423
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compounds by MTT assay (S3 Fig). Every compound reduced cell viability in a dose-dependent
manner. Compared with CCG-1423, the cytotoxic effects of CCG-100602 and CCG-203971
were modest. Furthermore, the cytotoxic effect of the S-isomer of CCG-1423 was slightly but sig-
nificantly lower than that of the R-isomer of CCG-1423. However, such difference was not
observed in the cytotoxic effects between the stereoisomers of CCG-100602 and CCG-203971.
Computer-associated binding simulation of the stereoisomers of CCG-
1423
In previous study, we found that racemic CCG-1423 directly binds to the NLS of MRTF-A
(NB) and inhibits the binding of importin α/β1 heterodimer [13]. We therefore compared the
binding affinities of the respective stereoisomers of CCG-1423 for MRTF-A using Sepharose
coupled with racemic or chiral CCG-1423. The binding affinity for MRTF-A was decreased in
the following order: S> SR> R (Fig 6A). This finding well coincided with their biological
activities shown in Fig 3.
Crystal structure of MRTF-A RPEL domain (residues 67–186) is reported by Hirano and
Matsuura [10], in which two NLSs were unambiguously identified: NLS1 (118LKRK121) and
NLS2 (151LKLKRARLAD160). NLS2 is corresponded to NB, and the sequence of NB
(KLKRAR) within NLS2 is identified as a functional NLS of MRTF-A (8). We therefore per-
formed the docking simulation focused on NB binding pocket. The volume size of the trimmed
protein (boxed by grid in Fig 6B) including NB biding pocket is 5594 Å3 (19.00 Å × 16.67 Å ×
17.67 Å). Two stereoisomers were docked to this binding pocket. The S-isomer of CCG-1423
showed higher docking score (-4.30785 ± 0.16283 for the S-isomer and -3.43768 ± 0.27834 for
the R-isomer, P< 0.05), but the interactions based on hydrogen bond between respective iso-
mers and NB site were similar. Their docking patterns to NB binding pocket are shown in Fig
6C. Both the stereoisomers docked to NB binding pocket in a similar manner, but their binding
direction was opposition of left and right. These findings suggest that the S-isomer of CCG-
1423 exhibits a higher affinity for NB binding pocket than the R-isomer, but drastic difference
in their binding affinities is not found. On the other hand, Treisman and co-workers proposed
that importin α/β1 heterodimer interacts with a bipartite NLS including NB (B2 or NLS2) plus
another N-terminal basic domain (B3 or NLS1) in the second RPEL motif [9]. In order to get
another supportive evidence for the docking sites for CCG-1423, we performed the docking
simulation focusing on this domain. The docking models to the NLS1 binding pocket were
largely different between the S- and R-isomers (Fig 6D). Since the biological activities were not
dramatically different between two stereoisomers (Fig 3), the NLS1 binding pocket is not plau-
sible as the target site for CCG-1423.
Discussion
MRTF-A is functionally involved in several pathological conditions including cancer cell
migration and tissue fibrosis [29]. MRTF-A therefore can be an attractive molecular target for
drug discovery and many researchers have paid attention to the screening of MRTF-A inhibi-
tor. In this study, we stereoselectively synthesized optically pure isomers of CCG-1423 and
related compounds and validated their biological activities. As a result, we found the
controls. Cells were stained with anti-MRTF-A antibody (red) and Hoechst (blue). Representative images of control cells and CCG-1423 treated cells are
shown (B). The images were analyzed as described in Materials and Methods: nuclear-specific localization [N], diffuse distribution in the nucleus and the
cytoplasm [NC], and cytoplasmic localization [C] (C). Each value represents the means ± SEMs of results from three independent experiments. Subcellular
localization of MRTF-A was statistically analyzed by a two-way ANOVA. The dose-dependent effects between CCG-1423 S and CCG-1423 R were
significantly different (P < 1 × 10−4). Significance levels were as follows: aP < 1 × 10−4 and bP < 1 × 10−4.
doi:10.1371/journal.pone.0136242.g005
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stereospecific effect of CCG-1423 on the cellular events activated by MRTF-A. Although Kim
et al. have recently reported the difference in the anti-EMT activity between the stereoisomers
of ginsenoside 20-Rg3 [31], this is a first report demonstrating the stereospecific biological
activities of chemical compounds inhibiting the MRTF-A function. These present findings pro-
vide useful information for the drug discovery focusing on the inhibition of MRTF-A function.
In this study, we successfully synthesized the target compounds from chiral starting materials.
The values of specific rotation ([α]D) of each pair of the stereoisomers strongly suggested that the
respective pairs are in mirror image relationship because only the +/–signs are different (Table 1).
The optical purity of synthetic compounds was clearly confirmed by chiral HPLC analysis, and
the enantiomeric excess of synthetic compounds was proved to be at least 98.8%. Based on these
observations, no apparent racemization occurred during the aforementioned synthetic process.
Fig 6. Docking simulation of the stereoisomers of CCG-1423. (A) In vitro binding of MRTF-A to each of the racemic or chiral CCG-1423. Purified in vitro
translated Flag-MRTF-A protein was incubated with Sepharose coupled with each of the racemic or chiral CCG-1423 or control Sepharose (cntl). Detailed
procedures are described in Materials and Methods. Flag-MRTF-A protein bound to the respective Sepharose was detected by IB with anti-DYKDDDDK
antibody. (B) The squared blue box is chosen for the docking simulation, which is constructed by MAKE_RECEPTOR. The volume size of this squared box is
5594Å3. (C) The NB docking site is excised from the crystal structure (3TPM). Chemical structures shown with orange color is the S-isomer of CCG-1423,
and green is for the R-isomer. Both isomers form hydrogen bonds between NH close to 3,5-dimethylbenzoyl moiety of CCG1423 and -CO- group of side
chain moiety of asparagine (ASN188). The hydrogen bond distances for the S- and R-isomers are 1.77Å and 2.02Å, respectively. Red and blue spheres are
electrostatically negative and blue fields for the receptor. (D) Docking simulation of the S-isomer (orange) and the R-isomer (green) of CCG1423 to NLS1
binding site. Red and blue fields are electrostatically negative and positive regions of the binding pocket.
doi:10.1371/journal.pone.0136242.g006
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Among the compounds that we tested, CCG-1423 only exhibits the stereoisomer-specific dif-
ferences in the inhibitory effects on MRTF-A/SRF-mediated cellular functions. The S-isomer of
CCG-1423 rather than the R-isomer potently suppressed the gene expression mediated by SRF
activation, cell migration, and nuclear import of MRTF-A (Figs 3, 4 and 5). However, CCG-
100602 and CCG-203791 did not exhibit such stereoisomer-specific differences. In accordance
with the finding that the binding affinity of the S-isomer CCG-1423 for MRTF-A was higher
that that of the R-isomer (Fig 6A), molecular docking simulation revealed that the S-isomer of
CCG-1423 shows modestly more stable binding to NB site, which is identified as a target site of
CCG-1423 in MRTF-A molecule (13). To enhance the binding affinity of the inhibitors for
MRTF-A, introducing of a covalent bond-forming functional group such asN-hydroxysuccini-
midyl or p-toluenesulfonyl esters into the inhibitors might be promising because NB of
MRTF-A is rich in nucleophilic lysine residue. Complex formation between the inhibitors and
NB would strongly inhibit the binding of importin α/β1 heterodimer to MRTF-A. Two benzene
ring of CCG-1423 and related compounds would be suitable site for introducing a covalent
bond-forming functional group because our docking simulation suggests that around the sites
of NB seem to be able to accommodate bulky substituents. Of interest, the R-isomer of CCG-
1423 had a greater cytotoxic effect than the S-isomer of CCG-1423 (S3 Fig). These results sug-
gest that CCG-1423 differently affect the MRTF-A-mediated cellular events and cell viability. In
contrast, CCG-100602 and CCG-203971 did not show such features.
In conclusion, our novel findings are as follows: (1) the S-isomer of CCG-1423, rather than
the R-isomer, shows higher potency in the inhibition of MRTF-A/SRF-mediated gene expres-
sion, cell migration, and serum-induced nuclear import of MRTF-A, (2) Molecular docking
simulation reveals that the S-isomer of CCG-1423 exhibits modestly higher binding affinity for
the NLS of MRTF-A than the R-isomer. These findings provide a valuable information
resource for drug design to block epithelial–mesenchymal transition.
Supporting Information
S1 Fig. High magnification images of Fig 3B. Bar = 25 μm.
(TIF)
S2 Fig. Analysis of subcellular localization of MRTF-A in B16F10 cells by immunoblot
(IB). B16F10 cells cultured in DMEM-10% serum were pre-treated with 3 μM of the indicated
compound or vehicle for 12 h, and then they were restimulated with serum for 15 min (final
serum concentration 20%). Their cytoplasmic (C) and nuclear (N) fractions were subjected to
IB with the indicated antibodies. Vehicle-treated B16F10 cells with or without serum restimu-
lation were used as controls. α−tubulin and histone H2B were used as loading controls for the
cytoplasmic and nuclear fractions, respectively. Representative results from two independent
experiments are shown.
(TIF)
S3 Fig. Effects of the stereoisomers of CCG-1423 and related compounds on the viability of
B16F10 cells. Viabilities of B16F10 cells treated with the indicated compounds were assayed
by MTT assay as described in Materials and Methods. The viability with vehicle only (cntl
DMSO) was set at 100%. Each value represents the means ± SEMs of results from three inde-
pendent experiments. Dose-dependent effects of the respective stereoisomers were analyzed
using a two-way ANOVA. The dose-dependent effects between CCG-1423 S and CCG-1423 R
were significantly different (P< 1 × 10−4). Significance level between bar garphs with a was
P = 0.0001.
(TIF)
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